Phase 3 Clinical Trials in 2018

2018 Phase 3 Research Overview

Phase 3 clinical trials started in 2018 provide a snapshot of the medical research landscape. In total, 13 such trials were initiated. 1 of these are still actively recruiting. 3 trials have been completed. Leading sponsors include National Cancer Institute (NCI), Vertex Pharmaceuticals Incorporated, Hoffmann-La Roche.

13
Phase 3 Trials
1
Recruiting
8
Sponsors

Trial Status

Top Sponsors (2018)

Phase 3 Trials Started in 2018

A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment - Followed by an Open-Label Crossover Extension Study Comprising Subcutaneous and Intravenous Natalizumab Administration

NCT03689972 · COMPLETED · Phase 3 · Biogen

Frequently Asked Questions

How many Phase 3 trials started in 2018?

13 Phase 3 clinical trials were started in 2018 according to ClinicalTrials.gov data tracked by ReadTheTrial.

What is Phase 3 in clinical trials?

Phase 3 trials are large-scale pivotal studies with 300-3,000+ participants for FDA approval.

Are any 2018 Phase 3 trials recruiting?

Yes, 1 Phase 3 trials from 2018 are still recruiting.

Explore More